Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent

Thrombosis Research

Volumn 125, Issue 5, 2010, Pages 457-463

  Nakatomi, Yasushi ^a   Nakashima, Teruhisa ^a   Gokudan, Soutaro ^a   Miyazaki, Hiroki ^a   Tsuji, Manami ^a   Hanada Dateki, Takako ^a   Araki, Tatsuya ^a   Tomokiyo, Kazuhiko ^a   Hamamoto, Takayoshi ^a   Ogata, Yoichi ^a  

^a KAKETSUKEN   (Japan)

Author keywords

APCC; bypassing agents; FVIIa; FX; hemophilia; inhibitors

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7A; THROMBIN;

ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MIXTURE; DRUG POTENTIATION; HEMOPHILIA A; HEMOSTASIS; HUMAN; IN VITRO STUDY; MOLECULAR WEIGHT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBIN TIME;

DRUG COMBINATIONS; FACTOR VIIA; FACTOR X; HEMOPHILIA A; HUMANS; PLASMA; THROMBIN;

EID: 77951667197     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.12.010     Document Type: Article

References (26)

1. Wight J., and Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 9 (2003) 418-435
2. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 138 (2007) 305-315
3. Treur M.J., McCracken F., Heeg B., Joshi A.V., Botteman M.F., De Charro F., and Van Hout B. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression. Haemophilia 15 (2009) 420-436
4. Astermark J., Donfield S.M., DiMichele D.M., Gringeri A., Gilbert S.A., Waters J., and Berntorp E. FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 109 (2007) 546-551
5. Key N.S., Christie B., Henderson N., and Nelsestuen G.L. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in haemophilia therapy. Thromb Haemost 88 (2002) 60-65
6. Schneiderman J., Rubin E., Nugent D.J., and Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 13 (2007) 244-248
7. Economou M., Teli A., Tzantzaroudi A., Tsatra I., Zavitsanakis A., and Athanassiou-Metaxa M. Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding. Haemophilia 14 (2008) 390-391
8. Livnat T., Martinowitz U., Zivelin A., and Seligsohn U. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma. Haemophilia 14 (2008) 782-786
9. Allen G.A., Persson E., Campbell R.A., Ezban M., Hedner U., and Wolberg A.S. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 27 (2007) 683-689
10. Prasad S., Lillicrap D., Labelle A., Knappe S., Keller T., Burnett E., Powell S., and Johnson K.W. Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood 111 (2008) 672-679
11. Tomokiyo K., Nakatomi Y., Araki T., Teshima K., Nakano H., Nakagaki T., Miyamoto S., Funatsu A., and Iwanaga S. A novel therapeutic approach combining human plasma-derived factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with factor VIIa alone. Vox Sang 85 (2003) 290-299
12. Tomokiyo K., Yano H., Imamura I., Nakano Y., Nakagaki T., Ogata Y., Terano T., Miyamoto S., and Funatsu A. Large-scale production and properties of human plasma-derived activated factor VII concentrate. Vox Sang 84 (2003) 54-64
13. Bajaj S.P., Rapaport S.I., and Brown S.F. Isolation and characterization of human factor VII. Activation of factor VII by factor Xa. J Biol Chem 256 (1981) 253-259
14. Di Scipio R.G., Hermodson M.A., Yates S.G., and Davie E.W. A comparison of human prothrombin, factor IX (Chrismas factor), factor X (Stuart factor), and protein S. Biochemistry 16 (1977) 698-706
15. Shima M. Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis. Semin Hematol. 41 Suppl 1 (2004) 125-131
16. Hemker H.C., Giesen P.L., Ramjee M., Wagenvoord R., and Beguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 83 (2000) 589-591
17. Turecek P.L., Varadi K., Keil B., Negrier C., Berntorp E., Astermark J., Bordet J.C., Morfini M., Linari S., and Schwarz H.P. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 33 (2003) 16-22
18. Komiyama, Pedersen A.H., and Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. Biochemistry 29 (1990) 9418-9425
19. Fair D.S., Plow E.F., and Edgington T.S. Combined functional and immunochemical analysis of normal and abnormal human factor X. J Clin Invest 64 (1979) 884-894
20. Váradi K., Negrier C., Berntorp E., Astermark J., Bordet J.C., Morfini M., Linari S., Schwarz H.P., and Turecek P.L. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 1 (2003) 2374-2380
21. Chen S.W., Pellequer J.L., Schved J.F., and Giansily-Blaizot M. Model of a ternary complex between activated factor VII, tissue factor and factor IX. Thromb Haemost 88 (2002) 74-82
22. Kittur F.S., Manithody C., and Rezaie A.R. Role of the N-terminal epidermal growth factor-like domain of factor X/Xa. J Biol Chem 279 (2004) 24189-24196
23. Ndonwi M., Broze Jr. G., and Bajaj S.P. The first epidermal growth factor-like domains of factor Xa and factor IXa are important for the activation of the factor VII-tissue factor complex. J Thromb Haemost 3 (2005) 112-118
24. Kenet G., Lubetsky A., Luboshitz J., and Martinowitz U. A new approach to treatment of bleeding episodes in young haemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 1 (2003) 450-455
25. Lindley C.M., Sawyer W.T., Macik B.G., Lusher J., Harrison J.F., Baird-Cox K., Birch K., Glazer S., and Roberts H.R. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 55 (1994) 638-648
26. Mori K., Sakai H., Nakano N., Suzuki S., Sugai K., Hisa S., and Goto Y. Congenital factor X deficiency in Japan. Tohoku J Exp Med 133 (1981) 1-19